Spruce Street Capital LP Makes New $3.97 Million Investment in Alto Neuroscience, Inc. $ANRO

Spruce Street Capital LP purchased a new position in Alto Neuroscience, Inc. (NYSE:ANRO) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 222,844 shares of the company’s stock, valued at approximately $3,967,000. Alto Neuroscience accounts for 1.3% of Spruce Street Capital LP’s portfolio, making the stock its 21st biggest holding. Spruce Street Capital LP owned about 0.72% of Alto Neuroscience at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Armistice Capital LLC boosted its holdings in Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares during the period. Vanguard Group Inc. boosted its holdings in Alto Neuroscience by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after acquiring an additional 20,702 shares during the period. Vivo Capital LLC purchased a new position in Alto Neuroscience in the 4th quarter worth approximately $18,433,000. Marshall Wace LLP boosted its holdings in Alto Neuroscience by 9.9% in the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after acquiring an additional 84,417 shares during the period. Finally, Millennium Management LLC boosted its holdings in Alto Neuroscience by 4.3% in the 3rd quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock worth $1,269,000 after acquiring an additional 12,896 shares during the period.

Wall Street Analyst Weigh In

ANRO has been the subject of a number of analyst reports. Bank of America initiated coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target for the company. Wedbush raised their price objective on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Jefferies Financial Group restated a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday, March 16th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, May 27th. Finally, Weiss Ratings upgraded Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Trading Down 1.6%

NYSE:ANRO opened at $21.14 on Tuesday. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average is $22.71 and its two-hundred day moving average is $19.61. Alto Neuroscience, Inc. has a 52 week low of $2.15 and a 52 week high of $28.44. The company has a market cap of $741.63 million, a PE ratio of -8.73 and a beta of 1.24.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). On average, analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.